Astrazeneca Pharma India Ltd
ASTRAZENAstrazeneca Pharma India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +62.0% against a −12.0% price move — the market has not yet caught up with the delivery.
The price is in a downtrend (15 weeks in) while the P/E sits at the 46th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −22.4% year on year, and 17% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Astrazeneca Pharma India Ltd trades at ₹8,024, in a downtrend and 15 weeks into that stage. That is −5.6% against its own 200-day average. It sits at 6% of a 52-week range of ₹7,931 to ₹9,555. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (12 weeks and counting).
Today the stock is in a downtrend — week 15 of stage 4, confirmed. At ₹8,024 it trades −5.6% versus its 200-day average and sits at 6% of its 52-week range (₹7,931–₹9,555).
Against the market, two honest reads. Cumulative: over the last 10.3 years the stock moved +536% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (12 weeks and counting; last ahead the week of 2026-05-29) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 46th percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Astrazeneca Pharma India Ltd trades at 105.0× P/E, mid-range by its own standards (46th percentile). Its long-run median P/E is 107.1×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 105.0× is mid-range by its own standards (46th percentile), against a long-run median of 107.1× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +62.0% against a −12.0% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +17.9%/yr price move, ~+15.8%/yr came from earnings growth and ~+2.1 pp from the multiple (expanding); over 10y, of the +22.7%/yr price move, ~+28.9%/yr came from earnings growth and ~−6.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Astrazeneca Pharma India Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −30.9% at the trough to +63.5% off a 5-quarter-old trough, ROCE slipping at 28.3%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +32.6% | +31.4% | +22.8% | +15.0% |
| Profit | +62.1% | +23.8% | +15.1% | +43.7% |
| EPS | +62.0% | +23.6% | +15.0% | +43.0% |
| Share price | −12.0% | +28.9% | +17.9% | +22.7% |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
39.8/100 — rank 7 of 8 in Pharma - MNC bulk Drugs · 83% evidence confidence
Astrazeneca Pharma India Ltd scores 39.8 out of 100 against the 8 companies it is compared with in Pharma - MNC bulk Drugs, ranking 7. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 16.3 + 8.4 + 4.3 + 10.8 = 39.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Astrazeneca Pharma India Ltd reported ₹579 Cr of revenue in the Mar 26 quarter, +20.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 15.0% a year. The last full year, FY26, came in at ₹2,276 Cr. The last four reported quarters add to ₹2,276 Cr.
Astrazeneca Pharma India Ltd reported ₹579 Cr of revenue in the Mar 26 quarter, +20.6% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 15.0% a year. The last full year, FY26, came in at ₹2,276 Cr. The last four reported quarters add to ₹2,276 Cr.
FY26 revenue came in at ₹2,276 Cr (+32.6% on the year), capping 10 years at 15.0% compound. The latest quarter (Mar 26) printed ₹579 Cr, +20.6% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +33.1% growth against the decade's 15.0% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +32.6% over the last 4 quarters against +32.6%/yr over the last 8 — stabilising; TTM profit +63.5% vs +8.1%/yr — accelerating.
→ Revenue grew — did margins hold as it scaled? Next: 11.0% this quarter (−7.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Astrazeneca Pharma India Ltd's operating margin is 11.0% in the Mar 26 quarter, −7.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −3.0% to 17.0%. The current quarter sits inside that band.
Astrazeneca Pharma India Ltd's operating margin is 11.0% in the Mar 26 quarter, −7.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −3.0% to 17.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 11.0%, −7.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −3.0%–17.0%.
🚨 Why the margin moved: operating margin went −7.5 pp year on year while gross margin went −14.1 pp — the loss came mostly from the gross line: input costs and pricing.
→ Margins slipped — did that reach the bottom line? Next: profit −22.4% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Astrazeneca Pharma India Ltd earned ₹45.0 Cr of net profit in the Mar 26 quarter, −22.4% year on year. Full-year FY26 profit was ₹188 Cr. The 10-year compound rate is 43.7%. That is 7.8% of the quarter's revenue. The same quarter a year earlier earned ₹58.0 Cr. 1 of the last 12 reported quarters were loss-making.
Astrazeneca Pharma India Ltd earned ₹45.0 Cr of net profit in the Mar 26 quarter, −22.4% year on year. Full-year FY26 profit was ₹188 Cr. The 10-year compound rate is 43.7%. That is 7.8% of the quarter's revenue. The same quarter a year earlier earned ₹58.0 Cr. 1 of the last 12 reported quarters were loss-making.
Mar 26 profit was ₹45.0 Cr, −22.4% year on year. On the full year, FY26 printed ₹188 Cr (+62.1%), and the 10-year compound rate is 43.7%.
🚨 Why profit moved: revenue contributed +20.6% and the margin −7.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +8.7% vs revenue +33.1%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 17% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 17% of Astrazeneca Pharma India Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−15.0 Cr of operating cash against ₹188 Cr of profit. After ₹82.0 Cr of capital spending, ₹−97.0 Cr was left as free cash.
FY26: operating cash of ₹−15.0 Cr against reported profit of ₹188 Cr, leaving free cash of ₹−97.0 Cr after ₹82.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 17% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 17%: the cash cycle stretched 84 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 84 days — the next section's job is to find where the cash is stuck.
→ So follow the cash to where it goes. Next: the 99-day cycle, in money terms.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Astrazeneca Pharma India Ltd's cash conversion cycle runs 99 days in FY26, up from 15 days in FY21. Capital spending ran ₹131 Cr over the last 3 years. At FY26 sales of ₹2,276 Cr each day of that cycle holds about ₹6.2 Cr, so roughly ₹617 Cr sits inside the business at any moment.
FY26: debtors at 34 days, inventory at 272 days — roughly 8.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 99 days, looser than FY21's 15.
The full loop: cash goes out to suppliers and production on day 0; stock waits 272 days to sell; customers pay about 34 days after that; and suppliers themselves are paid at 207 days — netting out to the 99-day cycle.
In money terms: at FY26 sales of ₹2,276 Cr, each day of the cycle holds about ₹6.2 Cr — so the 99-day loop keeps roughly ₹617 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹131 Cr over the last 3 fiscal years against ₹84.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 29% and the ROIC − WACC spread is +23.9 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Astrazeneca Pharma India Ltd earns a ROCE of 29% in FY26. That is up from a trough of −13% in FY15. Return on invested capital clears the cost of that capital by +23.9 percentage points, so growth here adds value rather than only size. The wiring behind it is 8.3% net margin on 1.14× asset turns.
FY26 ROCE is 29%, recovered from a FY15 trough of −13% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 8.3% net margin × 1.14× asset turns × 2.28× balance-sheet leverage ≈ 21.6% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 35.9% − 12.0% = a +23.9 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.13.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Astrazeneca Pharma India Ltd carries total debt of ₹111 Cr against shareholder equity of ₹873 Cr as of Mar 26, a debt-to-equity of 0.13 — effectively unlevered. On the annual view that ratio went from 0.02 in FY22 to 0.13 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹111 Cr against shareholder equity of ₹873 Cr — a debt-to-equity of 0.13. On the annual view, debt-to-equity went from 0.02 (FY22) to 0.13 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions added 1.1 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions added 1.1 points of Astrazeneca Pharma India Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 6.1% of the company. Foreign institutions moved −0.1 points over the same window, to 2.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +1.1 points over 8 quarters to 6.1%; Foreign institutions: −0.1 points over 8 quarters to 2.7%; Promoters: +0.0 points over 8 quarters to 75.0%.
Why the register moved: domestic institutions drove it (+1.1 points) — steady accumulation by institutions reading the same numbers this page reads.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Astrazeneca Pharma India Ltd: the Z-score reads 14.42. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 14.42 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 14.42.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Astrazeneca Pharma India Ltd this page | 105.0× | ₹20,014 Cr | Mixed | |||
| Abbott India Ltd | 38.5× | ₹59,511 Cr | Consistent | |||
| Glaxosmithkline Pharmaceuticals Ltd | 44.3× | ₹42,594 Cr | Consistent | |||
| Pfizer Ltd | 27.9× | ₹21,152 Cr | Mixed | |||
| Procter & Gamble Health Ltd | 34.1× | ₹11,145 Cr | Improving | |||
| Sanofi Consumer Healthcare India Ltd | 42.6× | ₹10,766 Cr | No read | |||
| Sanofi India Ltd | 17.6× | ₹7,805 Cr | — | No read | ||
| Novartis India Ltd | 41.4× | ₹4,052 Cr | Topping out |
Frequently asked questions
What is Astrazeneca Pharma India Ltd's share price today?
Astrazeneca Pharma India Ltd trades at ₹8,024, −12.0% over the past year. The company is valued at ₹20,014 Cr. The stock sits at 6% of its 52-week range of ₹7,931–₹9,555, −5.6% versus its 200-day average. On the tape, the price is in a downtrend, 15 weeks in. — as of 24 July 2026.
What were Astrazeneca Pharma India Ltd's latest quarterly results?
Astrazeneca Pharma India Ltd reported revenue of ₹579 Cr and net profit of ₹45.0 Cr for the Mar 26 quarter. Revenue rose 20.6% and profit fell 22.4% year on year. Earnings per share were ₹17.95. The operating margin was 11.0%, 7.0 pp lower than a year earlier. — as of 24 July 2026.
What is Astrazeneca Pharma India Ltd's revenue?
Astrazeneca Pharma India Ltd reported revenue of ₹579 Cr in the Mar 26 quarter, +20.6% year on year. For the full FY26 fiscal year, revenue was ₹2,276 Cr (+32.6%). Over the last 10 years revenue compounded at 15.0% a year. — as of 24 July 2026.
What is Astrazeneca Pharma India Ltd's profit?
Astrazeneca Pharma India Ltd earned ₹45.0 Cr of net profit in the Mar 26 quarter, −22.4% year on year. Full-year FY26 profit was ₹188 Cr. The operating margin ran 11.0% in the latest quarter. — as of 24 July 2026.
What is Astrazeneca Pharma India Ltd's market cap?
Astrazeneca Pharma India Ltd's market capitalisation is ₹20,014 Cr at a share price of ₹8,024. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Astrazeneca Pharma India Ltd's P/E ratio?
Astrazeneca Pharma India Ltd trades at a P/E of 105.0×, at the 46th percentile of its own 10-year range, against a long-run median of 107.1×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Astrazeneca Pharma India Ltd pay a dividend?
Yes — Astrazeneca Pharma India Ltd's dividend payout was 48% of profit in FY26, and it recorded a payout in 7 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Astrazeneca Pharma India Ltd overvalued?
On its own history, Astrazeneca Pharma India Ltd looks mid-range against its own history: its P/E of 105.0× sits at the 46th percentile of its 10-year range (long-run median 107.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Astrazeneca Pharma India Ltd growing?
Not right now — Astrazeneca Pharma India Ltd's latest numbers are shrinking: latest-quarter revenue +20.6% year on year, profit −22.4%, and the margin −7.0 pp at 11.0%. The 10-year compound rates are 15.0% (revenue) and 43.7% (profit). The earnings engine currently reads: deteriorating — as of 24 July 2026.
How is Astrazeneca Pharma India Ltd performing?
Astrazeneca Pharma India Ltd is in a downtrend, 15 weeks in. Its latest quarter's revenue rose 20.6% and profit fell 22.4% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 12 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Astrazeneca Pharma India Ltd in?
Turning around — profit growth swung from −30.9% at the trough to +63.5% off a 5-quarter-old trough, ROCE slipping at 28.3%. The read comes from the last 12 quarters of growth (revenue growth +32.6% latest, profit growth +63.5% latest, eps growth +62.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Astrazeneca Pharma India Ltd in an uptrend?
No — the price is in a downtrend (week 15 of stage 4), trading −5.6% versus its 200-day average and at 6% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Astrazeneca Pharma India Ltd beating the market?
Not lately — on a trailing-13-week view Astrazeneca Pharma India Ltd is currently behind the NIFTY 500 (12 weeks and counting; last ahead the week of 2026-05-29), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.3 years the stock moved +536% against the NIFTY 500's +274% — ahead of the index over the full window. — as of 24 July 2026.
Will Astrazeneca Pharma India Ltd's share price go up?
This page publishes no price forecast for Astrazeneca Pharma India Ltd. What it measures instead: the share price is ₹8,024, the price is in a downtrend 15 weeks in. Its P/E of 105.0× sits at the 46th percentile of its own 10-year range. — as of 24 July 2026.
Who owns Astrazeneca Pharma India Ltd?
Promoters hold 75.0% of Astrazeneca Pharma India Ltd, foreign institutions 2.7%, domestic institutions 6.1% and the public 16.2% (latest quarter). The biggest move on the register over the last two years: Domestic institutions added 1.1 points over 8 quarters. — as of 24 July 2026.
Does Astrazeneca Pharma India Ltd have too much debt?
No — Astrazeneca Pharma India Ltd's debt-to-equity is 0.13, and operating profit covers the interest bill 66×. FY26 borrowings were ₹111 Cr against equity of ₹873 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Astrazeneca Pharma India Ltd's capex?
Astrazeneca Pharma India Ltd spent ₹131 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹82.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Astrazeneca Pharma India Ltd's cash flow?
Astrazeneca Pharma India Ltd generated ₹−15.0 Cr of operating cash flow in FY26 and ₹−97.0 Cr of free cash flow after ₹82.0 Cr of capital spending. Reported profit that year was ₹188 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Astrazeneca Pharma India Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 17% of Astrazeneca Pharma India Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹−15.0 Cr against reported profit of ₹188 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Astrazeneca Pharma India Ltd?
On the balance sheet, the Z-score reads 14.42 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Astrazeneca Pharma India Ltd in its business cycle?
Astrazeneca Pharma India Ltd's FY26 operating margin was 12.0%, against a 13-year band of −3.0%–17.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 11.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Astrazeneca Pharma India Ltd story?
The sharpest disagreement: annual EPS moved +62.0% against a −12.0% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Astrazeneca Pharma India Ltd a stock worth studying right now?
This is not investment advice. The machine read: Astrazeneca Pharma India Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.